Results 201 to 210 of about 315,972 (272)

Cumulative exposure to tacrolimus is associated with increased risk of malignancy for solid organ transplant recipients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Long‐term immunosuppression in solid organ transplant recipients (SOTRs) is linked to increased cancer risk. Although this risk potentially increases with greater immunosuppressant exposure, the exact dose‐response pattern remains uncertain.
Sergio A. Acuna   +10 more
wiley   +1 more source

Increased cervical cancer incidence in the target age of screening—Variation by mode of detection

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cervical cancer rates have risen in several high‐income countries despite advances in screening. Here, using data on cervical cancer diagnoses between 1996 and 2022 in Finland, the authors examined incidence trends according to detection mode—screening, between screenings, or outside screening programs—with attention to the role of human ...
Jenna Snellman   +4 more
wiley   +1 more source

The impact of time‐to‐recurrence on post‐recurrence mortality in stage I–III colorectal cancer: A nationwide Danish cohort study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) recurrence is a significant threat to survival despite surgery with curative intent. The characteristics of CRC recurrence, however, remain poorly understood, challenging postoperative surveillance. This study investigated post‐recurrence mortality and associations between time‐to‐recurrence and mortality among stage
Jesper Nors   +3 more
wiley   +1 more source

Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology– and European Randomized Study of Screening for Prostate Cancer–based strategies

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Although screening reduces prostate cancer mortality, concerns about overdiagnosis and unnecessary biopsies have given rise to more tailored strategies. The European Association of Urology (EAU) proposed a risk‐adapted screening strategy combining prostate‐specific antigen (PSA)‐based intervals, a risk calculator, and magnetic resonance ...
Zhenwei Yang   +5 more
wiley   +1 more source

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld   +8 more
wiley   +1 more source

Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years. [PDF]

open access: yesBlood Adv
Liu Q   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy